Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
| ▸ | MMEL1 | Q495T6 | 5/20 | 0.35 |
| ▸ | MME | P08473 | 11/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL655001 | 1.00 | CTSA (0.38) | CTSAMMEL1MMEAPLNR | |
| SCHEMBL654742 | 0.91 | MME (0.35) | MME | |
| SCHEMBL654743 | 0.91 | MME (0.35) | MME | |
| SCHEMBL656768 | 0.91 | CTSA (0.38) | CTSAMMEL1MME | |
| SCHEMBL656769 | 0.91 | CTSA (0.38) | CTSAMMEL1MME | |
| SCHEMBL653745 | 0.88 | PYGL (0.33) | MME | |
| SCHEMBL1083085 | 0.88 | PYGL (0.33) | MME | |
| SCHEMBL652489 | 0.87 | HDAC3 (0.39) | CTSAMMEL1MMEAPLNR | |
| SCHEMBL652488 | 0.87 | HDAC3 (0.39) | CTSAMMEL1MMEAPLNR | |
| SCHEMBL655835 | 0.87 | CTSA (0.38) | CTSAMMEL1MMEAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451782-B1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-8822522-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130245041-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-09-19 | — | — | US | disclosed |
| US-8350027-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120259113-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| EP-2451782-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-8119634-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110275634-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-7956054-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110009409-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-13 | — | — | US | disclosed |
| WO-2011005674-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259113-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | CTSA 842/4885MMEL1 635/4885MME 10/4885 |
| US-20110009409-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | CTSA 842/4885MMEL1 635/4885MME 10/4885 |
| US-20130245041-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | CTSA 842/4885MMEL1 635/4885MME 10/4885 |
| US-20110275634-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | CTSA 949/4885MMEL1 695/4885MME 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.